Patents Assigned to Amgen Inc.
  • Patent number: 11028180
    Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 8, 2021
    Assignee: AMGEN INC.
    Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
  • Publication number: 20210164010
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Application
    Filed: December 14, 2020
    Publication date: June 3, 2021
    Applicant: Amgen Inc.
    Inventors: Chung-Jr HUANG, Xiaoming YANG
  • Publication number: 20210163621
    Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.
    Type: Application
    Filed: April 10, 2019
    Publication date: June 3, 2021
    Applicants: AMGEN INC., KiTe Pharma, Inc.
    Inventors: Michael John Giffin, Melissa THOMAS, Christopher MURAWSKY, Ryan B. CASE, Lawren WU, Jed J. WILTZIUS, Ruben Alvarez RODRIGUEZ, Jun FENG
  • Patent number: 11020537
    Abstract: A cassette for use with an injector has a housing, and a cassette identification arrangement (cassette ID) defining a code containing information about the cassette that is detectable and decipherable by an injector. The cassette may further have a sleeve movably disposed within the housing, for holding a drug container, and a locking arrangement for interlocking the sleeve with the housing. The cassette may further have an aperture in the housing, and a cassette cap for removing a needle shield of the drug container. The cassette may have an anti-bending structure to prevent bending or flexing of the cassette cap. The injector may have a processor for controlling operational parameters of the injector and a detector communicatively coupled with the processor for detesting and communicating the cassette ID to the microprocessor to decipher the code defined therein. Also, a method of injecting a drug into a patient with an injector, wherein the sequence of actions performed by the user are controlled.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: June 1, 2021
    Assignee: AMGEN INC.
    Inventors: R. Paul Mounce, Clinton Judd, Suhas Krishna, Neal Johnston, Gordon Johnston, Giorgio Sardo, Gabriele Ganzitti, Hong Jun Yeh
  • Patent number: 11020395
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 1, 2021
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden
  • Patent number: 11021493
    Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2?, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 1, 2021
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Matthew P. Bourbeau, James A. Brown, Ning Chen, Michael J. Frohn, Zice Fu, Longbin Liu, Qingyian Liu, Liping H. Pettus, Wenyuan Qian, Corey Reeves, Aaron C. Siegmund
  • Patent number: 11016099
    Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 25, 2021
    Assignees: AMGEN INC., MEDIMMUNE, LLC
    Inventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
  • Publication number: 20210147500
    Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 20, 2021
    Applicant: AMGEN INC.
    Inventors: YuMei XIONG, Kenneth William WALKER, Murielle Marie VENIANT ELLISON
  • Publication number: 20210139912
    Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: December 12, 2018
    Publication date: May 13, 2021
    Applicant: AMGEN INC.
    Inventors: Ingrid RULIFSON, Justin K. MURRAY, Michael OLLMANN, Oliver HOMANN
  • Publication number: 20210139554
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 13, 2021
    Applicant: Amgen Inc.
    Inventors: Eric Alan BUTZ, Christy Ann THOMSON, Marc Alain GAVIN, Ian Nevin FOLTZ, Dong XIA, Dina N. ALCORN, Randal Robert KETCHEM, Ai Ching LIM, Kathy MANCHULENKO, Laura SEKIROV, Kelly Ann BERRY, Cyr Clovis Chua DE IMUS, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Li LI
  • Patent number: 11001598
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 11, 2021
    Assignee: AMGEN INC.
    Inventor: Brian S. Lucas
  • Patent number: 10994112
    Abstract: A drug delivery device (100) includes a base (102) having a first region (104) with a drug delivery assembly (106) associated therewith. The drug delivery device also includes an antenna (112) disposed in the first region to radiate an electromagnetic field, the base defining a plane (114) and the antenna disposed in the plane of the base, and an electromagnetic field generator (116) selectively coupled to the antenna.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: May 4, 2021
    Assignee: AMGEN INC.
    Inventors: Stephanie Toy, Mark Ka Lai Lee, Donald Busby, Melissa D. Norton, Jeffrey Chen
  • Patent number: 10988485
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: April 27, 2021
    Assignee: Amgen Inc.
    Inventors: Ana Elena Minatti, Jonathan Dante Low, Ryan Paul Wurz, Brian Alan Lanman, Victor J. Cee, Michael D. Bartberger, Margaret Chu-Moyer
  • Patent number: 10988284
    Abstract: A sleeve for securing a cryogenic vial includes a cylindrical body sized to receive a vial, the body including a longitudinal axis, a first end, and a second end. A plurality of deformable members are disposed near the first end of the body and are arranged to deform from a first configuration to a second configuration. Each deformable member is displaced outwardly relative to the longitudinal axis of the body in the second configuration.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 27, 2021
    Assignee: AMGEN INC.
    Inventors: Anthony Bantug, Wael Mismar, Kenneth Tan, Tark Abed, Justin Allen Marsh, Mario Bogdan, Scott Comiso, Brian Schryver
  • Patent number: 10991458
    Abstract: Methods and systems for determining that a medical delivery device has been activated may be provided. According to certain aspects, a user captures a first image to determine if a medical delivery device is ready to be activated. The first image is transmitted to a health care provider which verifies that the medical delivery device should be activated. If the medical delivery device is to be activated, an electronic device instructs the user to activate the medical delivery device. Subsequently, the user transmits details about the activation of the medical delivery device to the health care provider to update a medical record.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: April 27, 2021
    Assignee: AMGEN INC.
    Inventors: Sabine Albrecht, Markus Bauss
  • Patent number: 10981999
    Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 20, 2021
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Publication number: 20210108212
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: October 26, 2020
    Publication date: April 15, 2021
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
  • Publication number: 20210095016
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 1, 2021
    Applicant: AMGEN INC.
    Inventors: Agnes E. HAMBURGER, Cen XU, Hong SUN, Yuan D. SHIH, Dohan WEERARATNE
  • Publication number: 20210094997
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 1, 2021
    Applicant: Amgen Inc.
    Inventors: Marc Alain GAVIN, Gunasekaran KANNAN, Li LI, Joshua Thomas PEARSON, Margaret KAROW
  • Patent number: 10962756
    Abstract: A system is described to facilitate the characterization of particles within a fluid contained in a vessel using an illumination system that directs source light through each vessel. One or more optical elements may be implemented to refract the source light and to illuminate the entire volume of the vessel. As the refracted source light passes through the vessel and interacts with particles suspended in the fluid, scattered light is produced and directed to an imager, while the refracted source light is diverted away from the imager to prevent the source light from drowning out the scattered light. The system can therefore advantageously utilize an imager with a large depth of field to accurately image the entire volume of fluid at the same time, facilitating the determination of the number and size of particles suspended in the fluid.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: March 30, 2021
    Assignee: AMGEN INC.
    Inventors: Dmitry Fradkin, Graham F. Milne, Thomas Clark Pearson